Search Results
Your search for 3 matches 15507 pages
Showing 1 - 50A Paradigm Shift In Treating Adult AML?
The scientific revolution in determining the genetic basis of cancer is finally bearing fruit in hematologic neoplasms such as acute myeloid leukemia (AML), where over the past decade a number of effective new drugs have expanded our armamentarium and provided effective—and in some cases...
VTE During Perioperative Therapy in Resectable and Borderline Resectable Pancreatic Cancer
As reported in the Journal of Clinical Oncology by Willems et al, venous thromboembolism (VTE) occurred in a high proportion of patients with resectable/borderline resectable pancreatic ductal adenocarcinoma receiving neoadjuvant FOLFOXIRI (5-fluorouracil, leucovorin, irinotecan, and oxaliplatin)...
Colorectal Cancer Liver Metastases: Transplant or Resect?
Colorectal metastases isolated to the liver no longer portend a universally fatal outcome. In 2024, the TransMet study1demonstrated that liver transplantation in select patients could be life-saving—thus changing the treatment paradigm—but so can surgical resection when appropriately applied....
ASH 2025: Highlights in Relapsed/Refractory Multiple Myeloma
“Dripping water hollows out stone, not through force but through persistence.” – Ovid The 2025 American Society of Hematology (ASH) Annual Meeting & Exposition delivered multiple practice-changing datasets surrounding T-cell–redirecting therapies in relapsed or refractory multiple myeloma....
World Cancer Day 2026: UICC’s Campaign ‘United by Unique’
As the organizer of World Cancer Day on February 4, the Union for International Cancer Control (UICC) is mobilizing organizations and individuals worldwide to ensure that the voices of people affected by cancer are heard and drive a new vision of cancer care. Now in its second year, the World...
Addition of Palbociclib to Standard Therapy in Hormone Receptor–Positive, HER2-Positive Metastatic Breast Cancer
In a phase III trial (PATINA) reported in The New England Journal of Medicine, Metzger et al found that the addition of palbociclib to anti-HER2 and endocrine therapies significantly prolonged progression-free survival in patients with hormone receptor–positive, HER2-positive metastatic breast...
Oxybutynin May Improve ADT-Induced Hot Flashes in Patients With Prostate Cancer
The use of oxybutynin led to statistically significant reductions in the number of hot flashes per day compared with placebo for men with prostate cancer receiving androgen-deprivation therapy (ADT), according to findings from the Alliance A222001 trial published in the Journal of Clinical...
Case 3: Management of Multiply Relapsed DLBCL
This is Part 3 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of multiply relapsed...
Case 1: Management of Early Relapsed DLBCL
This is Part 1 of Personalizing Treatment Pathways in Relapsed/Refractory DLBCL, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Jeremy Abramson, J. Erika Haydu, and Jacob Soumerai discuss the treatment of early relapsed...
Studies Move Away From Whole-Brain Radiotherapy Standard of Care for SCLC
When patients with small cell lung cancer (SCLC) progress, as is common with such an aggressive malignancy, brain metastasis is a known possibility. As such, guidelines have recommended prophylactic cranial irradiation for patients with SCLC who respond well to first-line therapy to decrease the...
Pirtobrutinib Improves Progression-Free Survival vs Bendamustine/Rituximab in Front-Line CLL/SLL
The first prospective, randomized phase III trial of a noncovalent Bruton’s tyrosine kinase (BTK) inhibitor exclusively in treatment-naive patients with chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)—BRUIN CLL-313—demonstrated a statistically significant and clinically...
New Four-Biomarker Blood Panel May Improve Early Detection of Pancreatic Cancer
Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer, and is most often diagnosed at advanced, unresectable stages, when 5-year survival is just 3%. The results from two retrospective phase II studies investigating blood biomarkers to detect early-stage pancreatic ductal...
Overall Survival With 3 vs 6 Months of Adjuvant Oxaliplatin Plus Fluoropyrimidine for Colorectal Cancer
As reported in the Journal of Clinical Oncology by Iveson et al, final results of the UK-based noninferiority phase III SCOT trial have shown noninferiority of 3 vs 6 months of adjuvant oxaliplatin plus fluoropyrimidine chemotherapy in overall survival among patients with colorectal cancer....
Adjuvant Aumolertinib in EGFR-Mutated NSCLC
As reported in The Lancet Oncology by Zhang et al, the Chinese phase III ARTS trial showed superior disease-free survival with the third-generation EGFR tyrosine kinase inhibitor aumolertinib as adjuvant therapy vs placebo in patients with completely resected stage II to IIIB EGFR-mutated non–small ...
Responses to Initial Pembrolizumab Support Treatment De-escalation in Cutaneous Squamous Cell Carcinoma
A response-adapted approach to treatment decision-making for patients with resectable cutaneous squamous cell carcinoma demonstrated that with the use of neoadjuvant pembrolizumab, many patients could avoid surgery and/or radiotherapy. Findings from the De-Squamate study were published in the...
Novel HER2-Targeted Bispecific Benefits Outcomes in Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
Ultrasound-Guided DOT May Reduce Unnecessary Breast Biopsies by Nearly 25%
A team of researchers and physicians found that utilizing ultrasound-guided diffuse optical tomography (DOT) technology may reduce unnecessary breast biopsy rates by nearly 25%. Using this new method first—rather than starting with a biopsy—may help to determine if additional diagnoses are needed...
Adjuvant Durvalumab in Resected Early-Stage NSCLC
In a phase III trial (Canadian Cancer Trials Group BR.31) reported in the Journal of Clinical Oncology, Goss et al found that adjuvant durvalumab did not improve disease-free survival vs placebo in patients with completely resected early-stage non–small cell lung cancer (NSCLC). Study Details In...
Consensus Recommendations Developed for Use of Liquid Nitrogen Spray Cryotherapy in Barrett's Esophagus, Esophageal Cancer
The Spray Cryotherapy Esophageal Consortium has developed a set of expert and evidence-based consensus recommendations guiding the use of liquid nitrogen spray cryotherapy in Barrett's esophagus and esophageal cancer. The recommendations, decided upon through a modified Delphi process, were...
Updated Analysis of CARTITUDE-4: Ciltacabtagene Autoleucel in Lenalidomide-Refractory Multiple Myeloma
As reported in The Lancet Oncology by Einsele et al, an updated analysis of the phase III CARTITUDE-4 trial has shown that a single infusion of ciltacabtagene autoleucel (cilta-cel), a B-cell maturation antigen–directed chimeric antigen receptor (CAR) T-cell therapy, prolonged overall survival vs...
Savolitinib Plus Osimertinib in Advanced EGFR-Mutant, MET-Amplified NSCLC
In an interim analysis of a Chinese phase III trial (SACHI) reported in The Lancet, Lu et al found that the combination of savolitinib and osimertinib prolonged progression-free survival vs chemotherapy in patients with advanced EGFR-mutated, MET-amplified non–small cell lung cancer (NSCLC). Study...
Chemoradiation Plus Atezolizumab in Limited-Stage Small Cell Lung Cancer
As reported in the Journal of Clinical Oncology by Higgins et al, the phase III NRG Oncology/Alliance LU005 trial showed no overall survival benefit with the addition of atezolizumab to concurrent chemoradiation (CRT) in patients with limited-stage small cell lung cancer (LS-SCLC). Study Details In ...
Is Long-Term PPI Use Associated With Increased Gastric Cancer Risk?
Long-term proton pump inhibitor (PPI) use may not be associated with an increased risk of gastric adenocarcinoma, according to findings from a Nordic health study published by Duru et al The BMJ. According to the report's authors, “This finding should offer relief for patients needing long-term...
Addition of Cetrelimab to Erdafitinib in Metastatic Urothelial Carcinoma With FGFR Alterations
In a phase II study (NORSE) reported in the Journal of Clinical Oncology, Loriot et al found that both erdafitinib monotherapy and the combination of erdafitinib and cetrelimab were active as first-line treatment in cisplatin-ineligible patients with metastatic urothelial carcinoma with FGFR...
Outcomes With Colorectal Cancer Screening Among Childhood Cancer Survivors Who Received Abdominopelvic Radiation
In a study reported in the Journal of Clinical Oncology, Yeh et al found that childhood cancer survivors who received abdominopelvic radiation, who are at increased risk of developing colorectal cancer, can benefit from early screening to reduce the risk of colorectal cancer and associated...
Cabozantinib and Temozolomide in Unresectable or Metastatic Leiomyosarcoma
In a phase II study reported in The Lancet Oncology, Monga et al found that dual targeting of vascular endothelial growth factor (VEGF) and mesenchymal epithelial transition factor receptor (MET) pathways with cabozantinib and temozolomide was of benefit in patients with unresectable or metastatic...
Pembrolizumab Plus Lenvatinib in Recurrent Gynecologic Clear Cell Carcinoma
In a phase II trial (LARA) reported in The Lancet Oncology, Ngoi et al found that the combination of pembrolizumab and lenvatinib was active in patients with recurrent gynecologic clear cell carcinoma. Study Details In the trial, 25 efficacy-eligible patients (27 in safety population) with at least ...
Nutrition, Muscle Loss Compromises Survival in Patients With Cervical Cancer Undergoing Chemoradiotherapy
A scoping review of cachexia, sarcopenia, and malnutrition in patients with locally advanced cervical cancer undergoing chemoradiotherapy revealed that women who lost at least 10% muscle mass during treatment had a six times higher mortality rate, regardless of their weight at the start of...
A Battle With My Blood
Editor’s note: On November 22, 2025—the 62nd anniversary of her grandfather President John F. Kennedy’s assassination—Tatiana Celia Kennedy Schlossberg published an essay in The New Yorker detailing her diagnosis of acute myeloid leukemia with chromosome 3 inversion, a rare and aggressive subtype...
Novel HER2-Targeted Bispecific Improves Outcomes in Patients With Gastroesophageal Cancer
In patients with advanced HER2-positive gastroesophageal adenocarcinoma, treatment with the bispecific antibody zanidatamab-hrii and chemotherapy, with or without the PD-1 inhibitor tislelizumab-jsgr, reduced the risk of disease progression or death by 35% over trastuzumab plus chemotherapy in the...
Evolving Treatment Landscape Spurs Living Guideline Update on Multiple Myeloma
ASCO, in collaboration with Ontario Health (Cancer Care Ontario), has published an update to their previous guideline on the treatment of multiple myeloma.1 This new guideline—which has been selected as an ASCO Living Guideline—reflects dramatic changes that have helped improve the management of...
Case 3: Metastatic HR-Positive/HER2-Negative Breast Cancer With PTEN Loss and Emergent ESR1 Mutation
This is Part 3 of Balancing Benefit and Burden: Managing Toxicities in HR-Positive/HER2-Negative Metastatic Breast Cancer, a three-part video roundtable series. Scroll down to watch the other videos from this roundtable. In this video, Drs. Neil Iyengar, Sara Tolaney, and William Gradishar...
Dual Antigen Targeting of Drug-Resistant Extramedullary Myeloma
In a phase II trial (RedirecTT-1) reported in The New England Journal of Medicine, Kumar et al found that the combination of talquetamab (anti–G protein–coupled receptor family C group 5 member D) and teclistamab (anti–B-cell maturation antigen) produced high response rates in patients with...
Limited or No State Regulation of STLD Health Plans Linked to Decreases in Timely Cancer Treatment Initiation
In 2018, the federal government expanded the coverage duration of short-term limited-duration (STLD) health plans from 3 months to less than 12 months, with the option to renew for a total duration of up to 36 months. Some states imposed more stringent regulations than those federally imposed or...
Meningiomas: Phase II Trial Shows Activity of Targeted Therapy
A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that the CDK 4/6 inhibitor abemaciclib may slow tumor growth in patients with aggressive meningiomas that have specific genetic mutations. The primary analysis of Alliance A071401 was published by Priscilla...
Investigational Vaccine Could Prevent Cancer Development in Lynch Syndrome Carriers
An investigational cancer vaccine, NOUS-209, has shown potential for intercepting precancerous and cancerous cells before the disease can develop in individuals with Lynch syndrome, thereby showing the potential to prevent cancer from developing in these high-risk individuals, according to findings ...
Intensity-Modulated Proton vs Photon Radiotherapy in Oropharyngeal Cancer
In a prespecified interim analysis of a phase III trial (University of Texas MD Anderson Cancer Center Clinical Trial Consortium trial) reported in The Lancet, Frank et al found that intensity-modulated proton therapy (IMPT) was noninferior to standard intensity-modulated photon radiation therapy...
Axillary Recurrence With or Without ALND in Patients With Residual Micrometastases After Neoadjuvant Chemotherapy for Breast Cancer
In an initial analysis of a retrospective cohort study (OPBC-07/microNAC) reported in The Lancet Oncology, Montagna et al found that available evidence did not provide support for axillary lymph node dissection (ALND) in all patients with ypN1mi disease in sentinel lymph nodes after neoadjuvant...
What Is Causing a Rise in Early-Onset Gastrointestinal Cancers, Including Pancreatic Cancer?
Although it’s been widely reported for years that colorectal cancer incidence has been increasing among younger adults under age 50 by between 1% and 2% annually since the mid-1990s,1 two new studies by Kimmie Ng, MD, MPH, Associate Chief of the Division of Gastrointestinal Oncology and Founding...
Breast Cancer Recurrence Risk Determined by Deep Learning Model Trained on Histopathologic Slides
A deep learning model demonstrated the ability to predict breast cancer recurrence risk and possible benefit from the addition of chemotherapy based on histopathologic images rather than genomic testing in patients with hormone receptor–positive, HER2-negative breast cancer, according to findings...
Novel Endocrine Therapy, Giredestrant, Improves Invasive Disease–Free Survival in Estrogen Receptor–Positive, HER2-Negative Early Breast Cancer
Giredestrant, a next-generation oral selective estrogen receptor degrader (SERD) and full antagonist, significantly improved invasive disease–free survival as adjuvant treatment for patients with estrogen receptor–positive, HER2-negative early breast cancer compared with standard-of-care endocrine...
Nivolumab Plus AVD Reduces Disease Progression Risk in Adolescents With Advanced Classical Hodgkin Lymphoma
A combination of nivolumab with AVD chemotherapy (doxorubicin, vinblastine, and dacarbazine) demonstrated a significant reduction in the risk of disease progression or death compared with brentuximab vedotin plus AVD in adolescent patients with newly diagnosed advanced classical Hodgkin lymphoma,...
Pirtobrutinib vs Ibrutinib in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
In a phase III trial (BRUIN CLL-314) reported in the Journal of Clinical Oncology, Woyach et al found that pirtobrutinib was associated with a noninferior objective response rate vs ibrutinib in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, while also being associated with...
Addition of Nivolumab to Docetaxel in ARPI-Pretreated, Chemotherapy-Naive Advanced Prostate Cancer
As reported in The Lancet Oncology by Fizazi et al, the phase III CheckMate 7DX trial showed no progression-free or overall survival benefit with the addition of nivolumab to docetaxel in patients with androgen receptor pathway inhibitor (ARPI)–pretreated and chemotherapy-naive metastatic...
Addition of Postoperative Nivolumab to Cisplatin and Radiotherapy in High-Risk Locally Advanced HNSCC
In a phase III trial (GORTEC 2018-01, NIVOPOST-OP) reported in The Lancet, Bourhis et al found that the addition of adjuvant nivolumab to cisplatin and radiotherapy improved disease-free survival in patients with high-risk, resected, locally advanced squamous cell carcinoma of the head and neck...
Molecular Profile–Based Adjuvant Treatment in High-Intermediate Risk Endometrial Cancer
In a European phase III trial (PORTEC-4a) reported in The Lancet Oncology, van den Heerik et al found that molecular profile–based adjuvant treatment produced favorable results in women with high-intermediate risk endometrial cancer and allowed patients with favorable risk to be spared adjuvant...
MajesTEC-3: ‘Unprecedented’ Benefit in Previously Treated Multiple Myeloma
For patients with previously treated multiple myeloma, the greatest risk reduction yet achieved in a phase III clinical trial was reported with the BCMA-directed CD3 T-cell engager teclistamab-cqyv plus daratumumab and hyaluronidase-fihj. Treatment with this combination resulted in an 83% reduction ...
In Head-to-Head Comparison, Fixed-Duration Treatment Noninferior to Continuous for Previously Untreated CLL
Based on the phase III CLL17 trial, a fixed duration of targeted treatment demonstrated noninferiority to continuous treatment with respect to progression-free survival in previously untreated patients with chronic lymphocytic leukemia (CLL). The findings were presented at the Plenary Session of...
Early Results Show Pirtobrutinib Matches Ibrutinib in BTK Inhibitor-Naive CLL
In the phase III BRUIN CLL-314 trial, response rates were found to be as good with the noncovalent Bruton's tyrosine kinase (BTK) inhibitor pirtobrutinib as with ibrutinib in both patients with treatment-naive and relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic...
Benefit of Azacitidine Plus Venetoclax Confirmed in AML
The combination of the hypomethylating agent azacitidine and the BCL2 inhibitor venetoclax is an established regimen in older, unfit patients with acute myeloid leukemia (AML). Now, a phase II randomized trial indicates potential for less intensive therapy in the newly diagnosed fit population. In...
